Develops cancer drugs for patients with non-small cell lung cancer.
Jun 2026Revenue $170M/yrExpenses $308M/yr
No trendCash runway ≈ 5.5 years from Jun 2026
Figures by year
When will Nuvation Bio be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $170M and expenses $308M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $62.9M | $276M | −$213M |
| Dec 2024 | $7.87M | $601M | −$593M |
| Dec 2023 | $0.00 | $99.8M | −$99.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.